The role of Toll-like receptors in chronic B cell malignancies

Leukemia and Lymphoma

Volumn 50, Issue 10, 2009, Pages 1573-1580

  Muzio, Marta ^a   Bertilaccio, Maria T S ^a   Simonetti, Giorgia ^a,b   Frenquelli, Michela ^a,c   Caligaris Cappio, Federico ^a,c  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

B cells; Chronic lymphocytic leukemia; Lymphoma; Myeloma; TLR

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; CYTOKINE; DEATH RECEPTOR; LEUCINE RICH REPEAT KINASE 2; OLIGONUCLEOTIDE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST;

ADAPTIVE IMMUNITY; B CELL LYMPHOMA; B LYMPHOCYTE; BURKITT LYMPHOMA; CELLULAR DISTRIBUTION; CHRONIC DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CYTOKINE PRODUCTION; DRUG PROTEIN BINDING; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOSTIMULATION; IMMUNOTHERAPY; INNATE IMMUNITY; LYMPHOCYTE ACTIVATION; LYMPHOPROLIFERATIVE DISEASE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODY FORMATION; ANTINEOPLASTIC AGENTS; APOPTOSIS; B-LYMPHOCYTES; CELL TRANSFORMATION, NEOPLASTIC; DRUG DESIGN; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LIGANDS; LYMPHOCYTE ACTIVATION; LYMPHOMA, B-CELL; LYMPHOPROLIFERATIVE DISORDERS; MICE; NEOPLASM PROTEINS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 70350771183     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190903115410     Document Type: Review

References (82)

1. Muzio M, Mantovani A. Toll-like receptors. Microbes Infect 2000;2:251-255.
2. Akira S. TLR signaling. Curr Top Microbiol Immunol 2006;311:1-16.
3. Pasare C, Medzhitov R. Toll-like receptors: linking innate and adaptive immunity. Microbes Infect 2004;6:1382-1387.
4. Lanzavecchia A, Sallusto F. Toll-like receptors and innate immunity in B-cell activation and antibody responses. Curr Opin Immunol 2007;19:268-274.
5. Muzio M, Ni J, Feng P, Dixit VM. IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science 1997;278:1612-1615.
6. MuzioM, Natoli G, Saccani S, Levrero M, Mantovani A. The human toll signaling pathway: Divergence of nuclear factor kappaB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6). J Exp Med 1998;187:2097-2101.
7. Akira S. Toll-like receptors: lessons from knockout mice. Biochem Soc Trans 2000;28:551-556.
8. Muzio M, Mantovani A. Toll-like receptors (TLRs) signalling and expression pattern. J Endotoxin Res 2001;7:297-300.
9. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Tolllike receptors. Nature 2002;416:603-607.
10. Ehlers M, Fukuyama H, McGaha TL, Aderem A, Ravetch JV. TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. J Exp Med 2006;203:553-561.
11. Lau CM, Broughton C, Tabor AS, et al. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med 2005;202:1171-1177.
12. Inohara, Chamaillard, McDonald C, Nunez G. NOD-LRR proteins: Role in host-microbial interactions and inflammatory disease. Annu Rev Biochem 2005;74:355-383.
13. Fritz JH, Ferrero RL, Philpott DJ, Girardin SE. Nod-like proteins in immunity, inflammation and disease. Nat Immunol 2006;7:1250-1257.
14. Garlanda C, Riva F, Polentarutti N, et al. Intestinal inflammation in mice deficient in Tir8, an inhibitory member of the IL-1 receptor family. Proc Natl Acad Sci USA 2004;101:3522-3526.
15. Wald D, Qin J, Zhao Z, et al. SIGIRR, a negative regulator of Toll-like receptor-interleukin 1 receptor signaling. Nat Immunol 2003;4:920-927.
16. Adachi O, Kawai T, Takeda K, et al. Targeted disruption of the MyD88 gene results in loss of IL-1-and IL-18-mediated function. Immunity 1998;9:143-150.
17. O'Neill LA. SIGIRR puts the brakes on Toll-like receptors. Nat Immunol 2003;4:823-824.
18. Medzhitov R, Barton GM. Toll-like receptor pathway. Sci Signal, 2009. Available at: http://stke.sciencemag.org/cgi/cm/ stkecm;CMP-8643. Accessed 23 August 2005.
19. Bernasconi NL, Onai N, Lanzavecchia A. A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood 2003;101:4500-4504.
20. Bourke E, Bosisio D, Golay J, Polentarutti N, Mantovani A. The toll-like receptor repertoire of human B lymphocytes: Inducible and selective expression of TLR9 and TLR10 in normal and transformed cells. Blood 2003;102: 956-963.
21. Ruprecht CR, Lanzavecchia A. Toll-like receptor stimulation as a third signal required for activation of human naive B cells. Eur J Immunol 2006;36:810-816.
22. Hornung V, Rothenfusser S, Britsch S, et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002;168:4531-4537.
23. Hasan U, Chaffois C, Gaillard C, et al. Human TLR10 is a functional receptor, expressed by B cells and plasmacytoid dendritic cells, which activates gene transcription through MyD88. J Immunol 2005;174:2942-2950.
24. Akashi-Takamura S, Miyake K. TLR accessory molecules. Curr Opin Immunol 2008;20:420-425.
25. Wagner M, Poeck H, Jahrsdoerfer B, et al. IL-12p70-dependent Th1 induction by human B cells requires combined activation with CD40 ligand and CpG DNA. J Immunol 2004;172:954-963.
26. Miura Y, Shimazu R, Miyake K, et al. RP105 is associated with MD-1 and transmits an activation signal in human B cells. Blood 1998;92:2815-2822.
27. Gavin AL, Hoebe K, Duong B, et al. Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science 2006;314:1936-1938.
28. Meyer-Bahlburg A, Rawlings DJ. B cell autonomous TLR signaling and autoimmunity. Autoimmun Rev 2008;7:313-316.
29. Isnardi I, Ng YS, Srdanovic I, et al. IRAK-4-and MyD88-dependent pathways are essential for the removal of developing autoreactive B cells in humans. Immunity 2008;29:746-757.
30. Fillatreau S, Manz RA. Tolls for B cells. Eur J Immunol 2006;36:798-801.
31. Bekeredjian-Ding I, Inamura S, Giese T, et al. Staphylococcus aureus protein A triggers T cell-independent B cell proliferation by sensitizing B cells for TLR2 ligands. J Immunol 2007;178:2803-2812.
32. Poeck H, Wagner M, Battiany J, et al. Plasmacytoid dendritic cells, antigen, and CpG-C license human B cells for plasma cell differentiation and immunoglobulin production in the absence of T-cell help. Blood 2004;103:3058-3064.
33. Huggins J, Pellegrin T, Felgar RE, et al. CpG DNA activation and plasma-cell differentiation of CD27-naive human B cells. Blood 2007;109:1611-1619.
34. Jiang W, Lederman MM, Harding CV, Rodriguez B, Mohner RJ, Sieg SF. TLR9 stimulation drives naive B cells to proliferate and to attain enhanced antigen presenting function. Eur J Immunol 2007;37:2205-2213.
35. Bernasconi NL, Traggiai E, Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002;298:2199-2202.
36. Gauld SB, Dal Porto JM, Cambier JC. B cell antigen receptor signaling: Roles in cell development and disease. Science 2002;296:1641-1642.
37. Kelaidi C, Rollot F, Park S, et al. Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas. Leukemia 2004;18:1711-1716.
38. Arcaini L, Paulli M, Boveri E, et al. Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles. Cancer 2004;100:107-115.
39. Ferreri AJ, Zucca E. Marginal-zone lymphoma. Crit Rev Oncol Hematol 2007;63:245-256.
40. Cavalli F, Isaacson PG, Gascoyne RD, Zucca E. MALT Lymphomas. Hematology Am Soc Hematol Educ Program 2001:241-258.
41. Forman D, Webb P, Parsonnet J. H pylori and gastric cancer. Lancet 1994;343:243-244.
42. Hussell T, Isaacson PG, Crabtree JE, S J. Helicobacter pylorispecific tumour-infiltrating T cells provide contact dependent help for the growth of malignant B cells in low-grade gastric lymphoma of mucosa-associated lymphoid tissue. J Pathol 1996;178:122-127.
43. Parsonnet J, Isaacson PG. Bacterial infection and MALT lymphoma. N Engl J Med 2004;350:213-215.
44. Zucca E, Bertoni F, Roggero E, et al. Molecular analysis of the progression from Helicobacter pylori-associated chronic gastritis to mucosa-associated lymphoid-tissue lymphoma of the stomach. N Engl J Med 1998;338:804-810.
45. Purdue MP, Lan Q, Wang SS, et al. A pooled investigation of Toll-like receptor gene variants and risk of non-Hodgkin lymphoma. Carcinogenesis 2009;30:275-281.
46. Nieters A, Beckmann L, Deeg E, Becker N. Gene polymorphisms in Toll-like receptors, interleukin-10, and interleukin-10 receptor a and lymphoma risk. Genes Immun 2006;7:615-624.
47. Forrest MS, Skibola CF, Lightfoot TJ, et al. Polymorphisms in innate immunity genes and risk of non-Hodgkin lymphoma. Br J Haematol 2006;134:180-183.
48. Hellmig S, Fischbach W, Goebeler-Kolve ME, Folsch UR, Hampe J, Schreiber S. Association study of a functional Tolllike receptor 4 polymorphism with susceptibility to gastric mucosa-associated lymphoid tissue lymphoma. Leuk Lymphoma 2005;46:869-872.
49. Mantovani A, Garlanda C. Inflammation and multiple myeloma: The Toll connection. Leukemia 2006;20:937-938.
50. Jego G, Bataille R, Geffroy-Luseau A, Descamps G, Pellat-Deceunynck C. PAMP are growth and survival factors for human myeloma cells through Toll-like receptors. Leukemia 2006;20:1130-1137.
51. Bohnhorst J, Rasmussen T, Moen SH, et al. Toll-like receptors mediate proliferation and survival of multiple myeloma cells. Leukemia 2006;20:1138-1144.
52. Chiron D, Pellat-Deceunynck C, Amiot M, Bataille R, Jego G. TLR3 ligand induces NF-{k}B activation and various fates of multiple myeloma cells depending on IFN-{a} production. J Immunol 2009;182:4471-4478.
53. Hamblin T. Is chronic lymphocytic leukemia a response to infectious agents? Leuk Res 2006;30:1063-1064. (Pubitemid 44037079)
54. Ghiotto F, Fais F, Valetto A, et al. Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemia. J Clin Invest 2004;113:1008-1016.
55. Chiorazzi N, Ferrarini M. B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. Annu Rev Immunol 2003;21:841-894.
56. Lanemo Myhrinder A, Hellqvist E, Sidorova E, et al. A new perspective: Molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. Blood 2008;111:3838-3848.
57. Stevenson FK, Caligaris-Cappio F. Chronic lymphocytic leukemia: Revelations from the B-cell receptor. Blood 2004;103:4389-4395. (Pubitemid 38745961)
58. Ghia P, Caligaris-Cappio F. The origin of B-cell chronic lymphocytic leukemia. Semin Oncol 2006;33:150-156.
59. Messmer BT, Albesiano E, Efremov DG, et al. Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J Exp Med 2004;200:519-525.
60. Stamatopoulos K, Belessi C, Moreno C, et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations. Blood 2007;109:259-270.
61. Belessi CJ, Davi FB, Stamatopoulos KE, et al. IGHV gene insertions and deletions in chronic lymphocytic leukemia: "CLL-biased" deletions in a subset of cases with stereotyped receptors. Eur J Immunol 2006;36:1963-1974.
62. Spaner DE, Masellis A. Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia. Leukemia 2007;21:53-60.
63. Grandjenette C, Kennel A, Faure GC, Bene MC, Feugier P. Expression of functional toll-like receptors by B-chronic lymphocytic leukemia cells. Haematologica 2007;92:1279-1281.
64. Muzio M, Scielzo C, Bertilaccio MT, Frenquelli M, Ghia P, Caligaris-Cappio F. Expression and function of toll-like receptors in chronic lymphocytic leukaemia cells. Br J Haematol 2009;144:507-516.
65. Longo PG, Laurenti L, Gobessi S, et al. The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease. Leukemia 2007;21:110-120.
66. Porakishvili N, Kulikova N, Jewell AP, et al. Differential expression of CD 180 and IgM by B-cell chronic lymphocytic leukaemia cells using mutated and unmutated immunoglobulin VH genes. Br J Haematol 2005;131:313-319.
67. Decker T, Peschel C. Effect of immunostimulatory CpGoligonucleotides in chronic lymphocytic leukemia B cells. Leuk Lymphoma 2001;42:301-307. (Pubitemid 32725586)
68. Jahrsdorfer B, Muhlenhoff L, Blackwell SE, et al. B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides. Clin Cancer Res 2005;11:1490-1499.
69. Jahrsdorfer B, Wooldridge JE, Blackwell SE, et al. Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells. J Leuk Biol 2005;77:378-387. (Pubitemid 40289568)
70. Jahrsdorfer B, Blackwell S, Weiner G. The effects of CpG ODN on CLL proliferation, apoptosis or phenotype could have an impact on its clinical utility. Leukemia 2007;21:2354-2355; author reply 2355-2356.
71. Decker T, Schneller F, Kronschnabl M, et al. Immunostimulatory CpG-oligonucleotides induce functional high affinity IL-2 receptors on B-CLL cells: Costimulation with IL-2 results in a highly immunogenic phenotype. Exp Hematol 2000;28:558-568.
72. Decker T, Schneller F, Sparwasser T, et al. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood 2000;95:999-1006.
73. Shi Y, White D, He L, Miller RL, Spaner DE. Toll-like receptor-7 tolerizes malignant B cells and enhances killing by cytotoxic agents. Cancer Res 2007;67:1823-1831.
74. Spaner DE, Shi Y, White D, et al. Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells. Leukemia 2006;20:286-295.
75. Decker T, Hipp S, Kreitman RJ, Pastan I, Peschel C, Licht T. Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides. Blood 2002;99:1320-1326.
76. Jahrsdorfer B, Hartmann G, Racila E, et al. CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. J Leukoc Biol 2001;69:81-88.
77. Decker T, Schneller F, Hipp S, et al. Cell cycle progression of chronic lymphocytic leukemia cells is controlled by cyclin D2, cyclin D3, cyclin-dependent kinase (cdk) 4 and the cdk inhibitor p27. Leukemia 2002;16:327-334.
78. Castro JE, Prada CE, Aguillon RA, et al. Thymidinephosphorothioate oligonucleotides induce activation and apoptosis of CLL cells independently of CpG motifs or BCL-2 gene interference. Leukemia 2006;20:680-688.
79. Ghia P, Strola G, Granziero L, et al. Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22. Eur J Immunol 2002;32:1403-1413.
80. Granziero L, Circosta P, Scielzo C, et al. CD100/Plexin-B1 interactions sustain proliferation and survival of normal and leukemic CD5+ B lymphocytes. Blood 2003;101:1962-1969.
81. Ghia P, Circosta P, Scielzo C, et al. Differential effects on CLL cell survival exerted by different microenvironmental elements. Curr Top Microbiol Immunol 2005;294:135-145.
82. Granziero L, Ghia P, Circosta P, et al. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood 2001;97:2777-2783.